Trial Information

Summary: A Single Ascending Dose Study of R1671 in Patients With Mild Intermittent Asymptomatic Asthma.

Status: Recruiting

Protocol Number: PP21029

Sponsor: Hoffmann-La Roche

Company Division: Pharmaceutical

Official Scientific Title: A randomized, double-blind, single ascending dose study to investigate the safety, tolerability, pharmacokinetics and effect on pharmacodynamic biomarkers of an intravenous infusion of R1671 in patients with mild, intermittent asymptomatic asthma

Brief Summary: This 8 arm study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of R1671 or placebo in patients with mild, intermittent, asymptomatic asthma. Patients will be randomized to receive placebo or R1671, at a starting dose of 0.0015mg, by intravenous infusion; this dose will be escalated in subsequent groups of patients after a satisfactory assessment of the data from the previous dose. The anticipated time on study treatment is <3 months, and the target sample size is <100 individuals. Target sample size is 64.

Study Phase: I

Study Design / Study Details:

  • Purpose: Treatment
  • Allocation: Randomized
  • Masking: Double Blind
  • Control: Placebo
  • Assignment: Parallel
  • Endpoints: Safety

Study Type:

Interventional

Condition: Asthma

Intervention Type: Drug

Intervention Name: R1671

Primary Outcome: 1. AEs, laboratory parameters, vital signs, ECG. Time frame: Throughout study 2. Serum concentration of R1671, and serum pharmacokinetic parameters. Time frame: Throughout study

Key Secondary Outcomes: 1. Pharmacodynamic biomarker sampling; skin prick test. Time frame: At intervals during study

Inclusion Criteria:

  • adult patients, 18-50 years of age;
  • mild, intermittent, asymptomatic asthma;
  • history of asthma for >=6 months;
  • non-smokers.

Exclusion Criteria:

  • females of childbearing potential, or lactating;
  • history of immunologically medicated disease;
  • systemic antineoplastic or immunomodulatory treatment in past 6 months.

Gender: Males or Females

Age Limits: Min: 18 Years Max: 50 Years

Accepts Healthy Volunteers: No

Anticipated Start Date: October, 2007

Trial Registration Date: 08/15/2007

Date Last Updated: 07/15/2008

Link To Trial Results

Contact:

Research Site:
Located In:
Burbank, CA 91505
Telephone: 973-235-5000 or 800-526-6367

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 21, 2008 at 3:19:17 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA